HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nitric oxide does not mediate but inhibits transformation and tumor phenotype.

AbstractUNLABELLED:
Although inducible nitric oxide synthase (iNOS) and nitric oxide (NO) are implicated in tumor pathology, their role in the early stages of carcinogenesis is not well defined. Tumor necrosis factor alpha (TNFalpha) induces iNOS and NO production in transformation-sensitive JB6 P+, but not in transformation-resistant JB6 P-, mouse epidermal cells. We tested the hypothesis that iNOS, by generating NO and reactive nitrogen species, mediates tumor promoter-induced transformation. Specific [N-[3-(aminomethyl)benzyl]acetamidine (1400W)] and non-specific (N(omega)-methyl-L-arginine) iNOS inhibitors significantly reduced TNFalpha-induced NO production in P+ cells but both iNOS inhibitors enhanced TNFalpha-induced anchorage-independent transformation, thus ruling out a mediator role and suggesting an inhibitor role for NO. Independent support for an inhibitor role came from the observation that the NO donor [(Z)-1-[N-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate (DETA/NO)] inhibited TNFalpha- and 12-O-tetradecanoylphorbol-13-acetate-induced transformation. DETA/NO treatment also suppressed tumor phenotype in tumorigenic JB6 RT101 (Tx) cells. Higher concentrations of DETA/NO induced apoptosis. The transformation inhibitory effect of lower DETA/NO concentrations may be attributable in part to inhibition by NO of NF-kappaB-dependent but not of AP-1-dependent transcription.
IN CONCLUSION:
(a) induction of iNOS and NO production does not mediate but actually prevents tumor promotion; (b) iNOS inhibitors enhance the transformation response, and therefore appear not to be appropriate as chemoprevention agents; and (c) NO has both chemopreventive and tumoricidal effects, suggesting promise in cancer chemoprevention and therapy.
AuthorsArindam Dhar, June M Brindley, Cristi Stark, Michael L Citro, Larry K Keefer, Nancy H Colburn
JournalMolecular cancer therapeutics (Mol Cancer Ther) Vol. 2 Issue 12 Pg. 1285-93 (Dec 2003) ISSN: 1535-7163 [Print] United States
PMID14707269 (Publication Type: Journal Article)
Chemical References
  • DNA Primers
  • NF-kappa B
  • Nitric Oxide Donors
  • Reactive Oxygen Species
  • Tumor Necrosis Factor-alpha
  • Nitric Oxide
  • Nitric Oxide Synthase
  • Nitric Oxide Synthase Type II
  • Nos2 protein, mouse
  • Tetradecanoylphorbol Acetate
Topics
  • Animals
  • Apoptosis (physiology)
  • Base Sequence
  • Cell Line
  • Cell Transformation, Neoplastic
  • DNA Primers
  • Mice
  • NF-kappa B (physiology)
  • Nitric Oxide (physiology)
  • Nitric Oxide Donors (pharmacology)
  • Nitric Oxide Synthase (metabolism)
  • Nitric Oxide Synthase Type II
  • Phenotype
  • Reactive Oxygen Species
  • Tetradecanoylphorbol Acetate (pharmacology)
  • Transcriptional Activation (physiology)
  • Tumor Necrosis Factor-alpha (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: